Rani Therapeutics Holdings, Inc. - 10-Q Filing

Rani Therapeutics reports Q3 2026 financial results featuring ongoing R&D and G&A expenses alongside complex equity structures including pre-funded warrants and restricted stock units.

SEC EDGAR ·

Tickers: $RANI

Read the full article at SEC EDGAR

More Regulatory news